Targeted treatment of oligorecurrent prostate cancer? +++

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00215-3/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_estro25&_hsenc=p2ANqtz-8muw2YGnDlg_LHDfSdqDxnRoQiPZIkJ8myrxBHzQS3Ni-TJ89q4BlsCydF3cIpID0yOlBkLv08Ghw41NLerM6gZQrmSA&_hsmi=360165517&utm_content=360165517&utm_source=hs_email Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V–STORM): a phase 2, open-label, randomised controlled trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00197-4/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_estro25&_hsenc=p2ANqtz-8GZqTDS1JQoTt99029SeCbKxlWtqo61y6XS1086QgV2t_QIPth427_b0CQ9mvLDsDXDQBUIvGiIQc-oipJTf5TxiQTxQ&_hsmi=360165517&utm_content=360165517&utm_source=hs_email Standard versus reduced-dose chemoradiotherapy in anal cancer (PLATO-ACT4): short-term results of a phase 2 randomised controlled trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00213-X/fulltext?dgcid=hubspot_email_conferencealerts_estro25&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-9BbA3Dq3sg0WznUQHEzaBGDtYsc8FE7-f-3eF60NLOGiXl9E3QmRorW2EVJZoa4-qjQUGn1sQYezWvIuWPjkdQ7tgk3A&_hsmi=360165517&utm_content=360165517&utm_source=hs_email